CalciMedica, Inc. Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount
CalciMedica, Inc. (CALC) had Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount of $0 as of 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount · last filed 2022-05-12
- 2022-03-31: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-12-31: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-09-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
- 2021-06-30: Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-11 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-14 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-05 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |